- Home
- BIRD vs ITRM Comparison
BIRD vs ITRM Comparison
Compare BIRD & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIRD | ITRM |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 24.3M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BIRD | ITRM |
|---|---|---|
| Price | $3.20 | $0.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.00 | $9.00 |
| AVG Volume (30 Days) | 73.7K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $189,757,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.45 | $0.14 |
| 52 Week High | $12.84 | $1.49 |
Technical Indicators
Market Signals| Indicator | BIRD | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 36.88 |
| Support Level | $2.45 | $0.14 |
| Resistance Level | $3.36 | $0.39 |
| Average True Range (ATR) | 0.33 | 0.03 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 44.59 | 21.61 |
Price Performance
Historical ComparisonAbout BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.